Shares of C R Bard Inc (NYSE:BCR) have received an average recommendation of “Hold” from the twelve ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $319.17.

Several equities research analysts recently commented on the company. ValuEngine cut C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Cowen reaffirmed a “hold” rating and set a $317.00 price objective on shares of C R Bard in a research report on Friday, November 3rd. Zacks Investment Research raised C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price objective on the stock in a research report on Tuesday, December 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of C R Bard in a research report on Thursday, October 26th. Finally, Barclays increased their price objective on C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research report on Monday, November 6th.

In other C R Bard news, VP John A. Deford sold 14,107 shares of the stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $333.48, for a total value of $4,704,402.36. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Frank Lupisella, Jr. sold 7,035 shares of the stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $334.70, for a total value of $2,354,614.50. Following the completion of the transaction, the vice president now directly owns 13,824 shares in the company, valued at approximately $4,626,892.80. The disclosure for this sale can be found here. In the last three months, insiders sold 114,602 shares of company stock worth $38,193,867. 0.80% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Stephens Inc. AR bought a new position in shares of C R Bard in the second quarter worth about $253,000. Choate Investment Advisors bought a new position in shares of C R Bard in the second quarter worth about $201,000. Profund Advisors LLC raised its stake in shares of C R Bard by 7.9% in the second quarter. Profund Advisors LLC now owns 3,146 shares of the medical instruments supplier’s stock worth $994,000 after buying an additional 231 shares during the period. Citigroup Inc. raised its stake in shares of C R Bard by 100.7% in the second quarter. Citigroup Inc. now owns 114,620 shares of the medical instruments supplier’s stock worth $36,232,000 after buying an additional 57,501 shares during the period. Finally, Public Sector Pension investment Board raised its stake in shares of C R Bard by 176.3% in the second quarter. Public Sector Pension investment Board now owns 45,133 shares of the medical instruments supplier’s stock worth $14,267,000 after buying an additional 28,800 shares during the period. 79.11% of the stock is currently owned by institutional investors.

C R Bard (NYSE:BCR) traded down $1.95 during trading on Tuesday, hitting $331.24. The company had a trading volume of 4,714,800 shares, compared to its average volume of 679,456. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37. C R Bard has a 12 month low of $222.42 and a 12 month high of $337.73. The stock has a market capitalization of $24,140.00, a PE ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52.

C R Bard (NYSE:BCR) last released its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the consensus estimate of $2.96 by $0.06. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. The company had revenue of $989.80 million for the quarter, compared to analysts’ expectations of $990.64 million. During the same period last year, the firm posted $2.64 earnings per share. C R Bard’s revenue was up 5.1% compared to the same quarter last year. research analysts anticipate that C R Bard will post 11.89 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2018/01/19/c-r-bard-inc-bcr-receives-319-17-average-price-target-from-brokerages.html.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.